NantHealth to Participate at the 2021 Jefferies London Healthcare Conference

MORRISVILLE, N.C.--(BUSINESS WIRE)-- NantHealth, Inc. (NASDAQ-GS: NH), a leading provider of enterprise solutions that help businesses transform complex data into actionable insights, today announced that the company will participate at the 2021 Jefferies London Healthcare Conference.

Management plans to host virtual one-on-one and small group meetings with institutional investors on November 18 and 19, 2021. For additional information or to schedule a meeting with NantHealth management, please contact your Jefferies representative.

About NantHealth, Inc.

NantHealth, a member of the NantWorks ecosystem of companies, provides enterprise solutions that help businesses transform complex data into actionable insights. By offering efficient ways to move, interpret and visualize complex and highly sensitive information, NantHealth enables customers in healthcare, life sciences, logistics, telecommunications and other industries to automate, understand and act on data while keeping it secure and scalable. NantHealth’s product portfolio comprises the latest technology in payer/provider collaboration platforms for real-time coverage decision support (Eviti and NaviNet), and data solutions that provide multi-data analysis, reporting and professional services offerings (Quadris). The OpenNMS Group, Inc., a NantHealth subsidiary, helps businesses monitor and manage network health and performance. For more information, visit nanthealth.com, follow us on Twitter, Facebook, LinkedIn and YouTube, and subscribe to our blog.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211104006013/en/

Investor Contact:
Robert Jaffe
424.288.4098
[email protected]

Source: NantHealth, Inc.

You May Also Be Interested In

• UAE Opens 15th UN Congress on Crime Prevention and Criminal Justice and Launches Pledge4Justice with First Pledge of Up to USD 5 Million
• Crypto News: Tokenized Assets Reach $46 Billion After CFTC Update While Pepeto and ETH Gain
• 2026 IMS | IASO Bio Presented First-in-Human Data of BCMA-Targeted In Vivo CAR-T Cell Therapy IASO206